2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Distribution and Incidence of Blood-Borne Infection among Blood Donors from Regional Transfusion Centers in Burkina Faso: A Comprehensive Study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          ABSTRACT

          There is a high prevalence of blood-borne infections in West Africa. This study sought to determine the seroprevalence of blood-borne infections, including hepatitis B virus (HBV), hepatitis C virus (HCV), HIV, and syphilis, in blood donors in Burkina Faso. Blood donors were recruited from 2009 to 2013 in four major cities in Burkina Faso of urban area (Ouagadougou) and rural area (Bobo Dioulasso, Fada N’Gourma, and Ouahigouya). Serology tests including hepatitis B surface antigen, anti-HCV, anti-HIV, and rapid plasma reagin test were used for screening and were confirmed with ELISA. Disease prevalence was calculated among first-time donors. Incidence and residual risk were calculated from repeat donors. There were 166,681 donors; 43,084 had ≥ 2 donations. The overall seroprevalence of HBV, HCV, HIV, and syphilis were 13.4%, 6.9%, 2.1%, and 2.4%, respectively. The incidence rates (IRs) of HBV, HCV, HIV, and syphilis infection were 2,433, 3,056, 1,121, and 1,287 per 100,000 person-years. There was lower seroprevalence of HBV and HCV in urban area than in rural area (12.9% versus 14.0%, P < 0.001; and 5.9% versus 8.0%, P < 0.001), and no difference in HIV (2.1% versus 2.1%, P = 0.25). The IRs of new HBV, HCV, HIV, and syphilis were 2.43, 3.06, 1.12, and 1.29 per 100,000 person-years, respectively. The residual risk was one per 268 donations for HBV, one per 181 donations for HCV, and one per 1,480 donations for HIV, respectively. In conclusion, this comprehensive study from four blood donation sites in Burkina Faso showed high HBV and HCV seroprevalence and incidence with high residual risk from blood donation.

          Related collections

          Most cited references18

          • Record: found
          • Abstract: found
          • Article: not found

          Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence.

          In efforts to inform public health decision makers, the Global Burden of Diseases, Injuries, and Risk Factors 2010 (GBD2010) Study aims to estimate the burden of disease using available parameters. This study was conducted to collect and analyze available prevalence data to be used for estimating the hepatitis C virus (HCV) burden of disease. In this systematic review, antibody to HCV (anti-HCV) seroprevalence data from 232 articles were pooled to estimate age-specific seroprevalence curves in 1990 and 2005, and to produce age-standardized prevalence estimates for each of 21 GBD regions using a model-based meta-analysis. This review finds that globally the prevalence and number of people with anti-HCV has increased from 2.3% (95% uncertainty interval [UI]: 2.1%-2.5%) to 2.8% (95% UI: 2.6%-3.1%) and >122 million to >185 million between 1990 and 2005. Central and East Asia and North Africa/Middle East are estimated to have high prevalence (>3.5%); South and Southeast Asia, sub-Saharan Africa, Andean, Central, and Southern Latin America, Caribbean, Oceania, Australasia, and Central, Eastern, and Western Europe have moderate prevalence (1.5%-3.5%); whereas Asia Pacific, Tropical Latin America, and North America have low prevalence (<1.5%). The high prevalence of global HCV infection necessitates renewed efforts in primary prevention, including vaccine development, as well as new approaches to secondary and tertiary prevention to reduce the burden of chronic liver disease and to improve survival for those who already have evidence of liver disease. Copyright © 2012 American Association for the Study of Liver Diseases.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study

            The 69th World Health Assembly approved the Global Health Sector Strategy to eliminate viral hepatitis by 2030. Although no virological cure exists for hepatitis B virus (HBV) infection, existing therapies to control viral replication and prophylaxis to minimise mother-to-child transmission make elimination of HBV feasible. We aimed to estimate the national, regional, and global prevalence of HBsAg in the general population and in the population aged 5 years in 2016, as well as coverage of prophylaxis, diagnosis, and treatment.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Seroprevalence and incidence of transfusion-transmitted infectious diseases among blood donors from regional blood transfusion centres in Burkina Faso, West Africa.

              The high prevalence of numerous transfusion-transmitted infectious diseases such as HIV, HBV, HCV and syphilis in sub-Saharan Africa affects blood safety for transfusion recipients. The aim of this study was to evaluate the prevalence and incidence of transfusion-transmissible infectious diseases among blood donors in Burkina Faso. A retrospective study of blood donors' records from January to December 2009 was conducted. Prevalence and incidence of viral infections were calculated among repeat and first-time blood donors. Of the total of 31405 first-time volunteer blood donors in 2009, 24.0% were infected with at least one pathogen and 1.8% had serological evidence of multiple infections. The seroprevalence of HIV, HBV, HCV and syphilis in first-time volunteer donors was 1.8%, 13.4%, 6.3% and 2.1%, respectively. In 3981 repeat donors, the incidence rate was 3270.2, 5874.1 and 6784.6 per 100000 donations for anti-HIV-1, HBsAg and anti-HCV, respectively. These numbers varied significantly according to populations where blood is collected and blood centres in Burkina Faso. The relatively high prevalence of viral markers in first-time volunteers and remarkably high incidence of infections in repeat donors raise concerns regarding the safety of these donors and suggest that implementation of NAT might significantly improve the situation. © 2011 Blackwell Publishing Ltd.
                Bookmark

                Author and article information

                Journal
                Am J Trop Med Hyg
                Am J Trop Med Hyg
                tpmd
                tropmed
                The American Journal of Tropical Medicine and Hygiene
                The American Society of Tropical Medicine and Hygiene
                0002-9637
                1476-1645
                April 2021
                22 February 2021
                22 February 2021
                : 104
                : 4
                : 1577-1581
                Affiliations
                [1 ]Gastroenterology and Hepatology, Mayo Clinic Rochester, Rochester, Minnesota;
                [2 ]Department of Medicine, University of Minnesota, Minneapolis, Minnesota;
                [3 ]Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA)/LABIOGENE, University of Ouaga I Joseph Ki Zerbo (JKZ), Ouagadougou, Burkina Faso;
                [4 ]Division of Biomedical Statistics and Informatics, Mayo Clinic Rochester, Rochester, Minnesota;
                [5 ]Division of Hematology and Medical Oncology, Mayo Clinic Arizona, Scottsdale, Arizona;
                [6 ]Centre National de Transfusion sanguine du Burkina Faso (National Center for Blood Transfusion in Burkina Faso), Ouagadougou, Burkina Faso;
                [7 ]School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, Louisiana
                Author notes
                [* ]Address correspondence to Bolni M. Nagalo, Division of Hematology and Medical Oncology, Mayo Clinic Arizona, 13400 E Shea Blvd., Scottsdale, AZ 85259. E-mail: nagalo.bolni@ 123456mayo.edu

                Financial support: This work was supported by Mayo Clinic Institutional funding.

                Authors’ addresses: Nicha Wongjarupong, University of Minnesota, Minneapolis, MN, E-mail: nwongjarupong@ 123456gmail.com . Sharad Oli, Maimonides Medical Center, Brooklyn, NY, E-mail: drsharadoli@ 123456gmail.com . Mahamoudou Sanou, Florencia Djigma, Alice Kiba Koumare, Albert T. Yonli, and Jacques Simpore, University of Ouaga I Joseph Ki Zerbo (JKZ), Ouagadougou, Burkina Faso, E-mails: mahamoudsanou@ 123456hotmail.com , florencia.djigma@ 123456gmail.com , alice_kiba@ 123456yahoo.fr , yonlitheo@ 123456yahoo.fr , and jacques.simpore@ 123456yahoo.fr . Mohamed A. Hassan, University of Pittsburgh, Pittsburg, PA, E-mail: hassan.mohamed.dr@ 123456gmail.com . Kristin Mara, William S. Harmsen, Terry Therneau, and Lewis R. Roberts, Mayo Clinic Rochester, Rochester, MN, E-mails: mara.kristin@ 123456mayo.edu , harmsen.william@ 123456mayo.edu , therneau@ 123456mayo.edu , and roberts.lewis@ 123456mayo.edu . Oumar Barro and Bolni M. Nagalo, Mayo Clinic Arizona, Phoenix, AZ, E-mails: barro.oumar@ 123456mayo.edu and nagalo.bolni@ 123456mayo.edu . Ghislaine Vodounhessi and Salam Sawadogo, National Center for Blood Transfusion in Burkina Faso, Ouagadougou, Burkina Faso, E-mails: ghislainetall1270@ 123456gmail.com and salemserein@ 123456hotmail.com . Jean Christopher Chamcheu, University of Louisiana at Monroe, Monroe, LA, E-mail: chamcheu@ 123456ulm.edu .

                Article
                tpmd200601
                10.4269/ajtmh.20-0601
                8045619
                33617474
                dd893c44-f51b-4458-91d4-51853efea74c
                © The American Society of Tropical Medicine and Hygiene

                Open Access statement. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and reproduction in any medium for non-commercial purposes, provided the original author and source are credited, a link to the CC License is provided, and changes – if any – are indicated.

                History
                : 05 June 2020
                : 20 December 2020
                Page count
                Pages: 5
                Categories
                Articles

                Infectious disease & Microbiology
                Infectious disease & Microbiology

                Comments

                Comment on this article